| Prevalence and risk factors of myocardial remodeling in hemodialysis patients. | |
| | |
MedLine Citation:
|
PMID: 19817519 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Left ventricular hypertrophy (LVH) is an independent risk factor for morbidity/mortality in patients with end stage renal disease (ESRD). Our study aimed to identify prevalence as well as independent risk factors that contribute to the development of LV geometric remodeling in our HD patients. METHODS: The left ventricles of 116 HD patients were classified echocardiographically into four different geometric patterns on the basis of LV mass and relative wall thickness. Furthermore, we measured inferior vena cava (IVC) diameter and its collapsibility index (CI) by echocardiography. Finally, we modeled a stepwise multiple regression analysis to determine the predictors of LV geometry. RESULTS: Our study provides evidence that HD patients had a prevalence of abnormal LV geometry in 92% and LVH in 81%. We found all four geometric models of LV. Most dominant were eccentric LVH. Concentric LVH was observed in 37, normal geometry (NG) in 9, and concentric remodeling (CR) in 13 of HD patients. Mean arterial blood pressure was significantly higher in the cLVH group (95 +/- 10 mmHg) than in the NG and CR groups (81.6 +/- 12.3 and 80 +/- 11.8, respectively, p < 0.001). The cLVH and eCLVH groups had significantly lower mean hemoglobin (10.3 +/- 1.4 g/dL and 10.6 +/- 1g/dL, respectively) compared with the NG group (11.9 +/- 1.4 g/dL), p < 0.001. Furthermore, interdialytic weight gain (kg) was significantly higher in eCLVH group (3.13 +/- 0.8) than in NG group (2.3 +/- 1.1), p < 0.001. Mean IVC index of the eLVH group (10.83 +/- 2.07 mm/m(2)) was significantly higher than corresponding indexes of NG (10.83 +/- 2.07 mm/m(2)), CR (8.31 +/- 1.32 mm/m(2)) and cLVH (8.12 +/- 2.06 mm/m(2)) groups (p < 0.001 for each comparisons). CONCLUSION: Mean arterial pressure, hemoglobin, IVC index, and interdialytic weight gain were found to be independent predictors of LV geometry (R(2) = 0.147; p < 0.001) in HD patients. |
| | |
Authors:
|
Zorica Dimitrijevic; Tatjana Cvetkovic; Miomir Stojanovic; Karolina Paunovic; Vidojko Djordjevic |
Related Documents
:
|
5645859 - Left ventricular function in patients with chronic obstructive pulmonary disease. 2949889 - Long-term results after the fontan operation for tricuspid atresia. 19593939 - Acute effect of transcatheter closure on right ventricular function in patients with at... 2470529 - Percutaneous balloon valvuloplasty in patients with severe aortic stenosis and low ejec... 7743619 - Effects of long-term enalapril therapy on cardiac structure and function in patients wi... 12025949 - Impairment of myocardial blood flow reserve in patients with asymptomatic left ventricu... 18388709 - Mobility in hurler syndrome. 6971489 - Monocyte cytotoxicity in connective tissue diseases. correlation with disease groups. 18676439 - Perivascular spaces--mri marker of inflammatory activity in the brain? |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Renal failure Volume: 31 ISSN: 1525-6049 ISO Abbreviation: Ren Fail Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-10-12 Completed Date: 2010-01-05 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8701128 Medline TA: Ren Fail Country: England |
Other Details:
|
Languages: eng Pagination: 662-7 Citation Subset: IM |
Affiliation:
|
Clinic of Nephrology, Clinical Center Nis, Serbia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Comorbidity Female Humans Hypertrophy, Left Ventricular / complications, epidemiology, physiopathology* Kidney Failure, Chronic / epidemiology, physiopathology*, therapy* Male Middle Aged Prevalence Renal Dialysis* Risk Factors Ventricular Remodeling* |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Acid-base balance in peritoneal dialysis patients: a Stewart-Fencl analysis.
Next Document: Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence.